Protease Inhibitor class drugs

8 results

  • evotaz

    (atazanavir and cobicistat)
    E.R. Squibb & Sons, L.L.C.
    EVOTAZ® is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents for adults and pediatric patients weighing at least 35 kg. Its use in treatment-experienced patients should be guided by baseline protease inhibitor resistance.

  • norvir

    (Ritonavir)
    AbbVie Inc.
    NORVIR is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents in adults and pediatric patients.

  • paxlovid

    (nirmatrelvir and ritonavir)
    Pfizer Laboratories Div Pfizer Inc
    PAXLOVID is indicated for the treatment of mild-to-moderate COVID-19 in adults at high risk for severe disease progression, including hospitalization or death. It is not approved for COVID-19 prevention via pre-exposure or post-exposure prophylaxis.

  • prezcobix

    (DARUNAVIR ETHANOLATE and COBICISTAT)
    Janssen Products LP
    PREZCOBIX is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents for both treatment-naïve and treatment-experienced adults and pediatric patients (weighing at least 40 kg) without specific darunavir resistance mutations.

  • prezcobix

    (DARUNAVIR ETHANOLATE and COBICISTAT)
    A-S Medication Solutions
    PREZCOBIX is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥40 kg), either treatment-naïve or experienced, when used with other antiretroviral agents and in the absence of specific darunavir resistance-associated substitutions.

  • prezista

    (darunavir)
    Janssen Products LP
    PREZISTA, when co-administered with ritonavir and other antiretroviral agents, is indicated for the treatment of HIV-1 infection in adults and pediatric patients aged 3 years and older.

  • reyataz

    (ATAZANAVIR)
    E.R. Squibb & Sons, L.L.C.
    REYATAZ® is indicated for the treatment of HIV-1 infection in adults and pediatric patients aged 3 months and older who weigh at least 5 kg, in combination with other antiretroviral agents. It is not recommended for patients under 3 months due to the risk of kernicterus.

  • symtuza

    (Darunavir, Cobicistat, Emtricitabine, and Tenofovir alafenamide)
    Janssen Products LP
    SYMTUZA is indicated for treating HIV-1 infection in adults and pediatric patients (≥ 40 kg) with no prior antiretroviral therapy or who are virologically suppressed on a stable regimen for at least 6 months, with no known resistance substitutions.